OBJECTIVES: Although drug-eluting stents (DESs) reduce the rate of target vessel revascularization compared with bare-metal stents, the results of DESs for patients with diabetes and multivessel coronary artery disease (CAD) in the DES era are inconsistent. This meta-analysis was undertaken to assess the efficacy and safety of coronary artery bypass grafting (CABG) compared with drug-eluting stent implantation in patients with diabetes mellitus and multivessel coronary artery disease.
INTRODUCTION
The optimal revascularization strategy for diabetic patients is an ongoing hot topic. Given the results of the BARI and ARTS I trials and a meta-analysis, coronary artery bypass surgery has been preferred to percutaneous coronary intervention (PCI) in diabetics with multivessel coronary artery disease (CAD) [1] [2] [3] . However, these recommendations were made before the availability of drugeluting stents (DESs), which have been shown to decrease in-stent restenosis and repeat revascularization compared with bare-metal stenting in patients with diabetes. The evidence from randomized trials in deciding the best choice for patients with diabetes and multivessel disease is limited. Recently, four multicentre random trials (FREEDOM, CARDia, SYNTAX and VA CARDS) have elucidated the optimal revascularization strategy for diabetic patients with multivessel disease. Therefore, we conducted a meta-analysis to compare coronary artery bypass grafting (CABG) with DES implantation to guide clinicians in deciding the best choice for patients with diabetes and multivessel disease.
METHODS

Search strategy and selection criteria
We conducted a search of Medline, EMBASE from January 2003 to July 2013 by two reviewers independently, using the terms 'coronary artery bypass graft surgery', 'DES', 'sirolimus-eluting stent', 'paclitaxel-eluting stent', 'diabetes mellitus' and 'multivessel disease', according to established criteria. Included studies must meet the following criteria: (i) compared the use of PCI to that of CABG in patients with diabetes mellitus and multivessel coronary artery disease (greater than or equal to two arteries) (ii) and using DES in the PCI arm (iii) had lengths of follow-up ≥ 12 months.
(i) major adverse cardiac events (MACEs) (death, myocardial infarction (MI) and repeat revascularization); (ii) death; (iii) myocardial infarction; (iv) repeat revascularization (target vessel revascularization or any urgent revascularization on the basis of clinical condition, including surgical or percutaneous intervention) and (v) stroke events. End point definitions were those of the individual studies included in the final analysis.
Data analysis
Odds ratios (ORs) and their 95% confidence interval (CI) were used to assess the difference between two groups. Heterogeneity was assessed by means of the Cochran Q heterogeneity test and considered significant when P < 0.10. The degree of inconsistency among studies with scores of 25, 50 and 75% represents, respectively, low, moderate and high. If the value I 2 was < 50%, then we think the heterogeneity was not significant [4] . For sensitivity analyses, a subgroup study was performed. Finally, we assessed publication bias using funnel plots.
Cochrane Collaboration meta-analysis software, Review Manager 5.0 was used to perform data analysis. Data were presented as mean ± SD; a P-value of 0.05 for any test or model was considered to be statistically significant.
RESULTS
A total of 13 articles comparing DESs with coronary artery bypass graft from January 2003 to July 2013 were identified by the screening electronic search strategy [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Figure 1 depicts the process of the search strategy, and Table 1 summarizes the characteristics of included studies. Nine were observational studies and four were randomized controlled trials (RCTs). The mean followup was 2.9 years (range 1-5).
Composite end point of death, myocardial infarction and repeat revascularization (major adverse cardiac event)
The OR and summary plot for MACEs showed that the overall analysis revealed a 34% statistically significant reduction in patients who underwent CABG (OR 0.51, 95% CI 0.46-0.58; Fig. 2 ). There was no statistically significant difference in mortality between the two revascularization strategies (OR 0.89, 95% CI 0.75-1.05; Fig. 3 ). There was a statistically significant reduction in MI between the two revascularization strategies (OR 0.64, 95% CI 0.50-0.83; Fig. 4 ). There was a significantly lower risk for repeat revascularization by 67.7% in patients treated with CABG compared with DES (OR 0.29, 95% CI 0.23, 0.35; Fig. 5 ) and a higher risk for stroke events in patients treated with CABG compared with DES (OR 2.09, 95% CI 1.45-3.02; Fig. 6 ).
At the 1-year follow-up, the OR and summary plot for MACEs showed that the overall analysis revealed a 41% significant reduction in patients who underwent CABG (OR 0.58, 95% CI 0.35-0.97). There was no significant difference between the two revascularization strategies in mortality (OR 0.64, 95% CI 0.39-1.04) MI (OR 1.17, 95% CI 0.67-2.03). There was a significantly lower risk for repeat revascularization in patients treated with CABG compared with DES (OR 0.78, 95% CI 0.63-0.96). There was a higher risk for stroke events in patients treated with CABG compared with DES (OR 4.98, 95% CI 1.54-16.07).
During 1-4 years, the OR and summary plot for MACEs showed a significant reduction in patients who underwent CABG (OR 0.65, 95% CI 0.46-0.91). There was no significant difference between the two revascularization strategies in mortality (OR 0.81, 95% CI 0.60-1.09) or MI (OR 0.21, 95% CI 0.72-2.04). There was a significantly lower risk for repeat revascularization in patients treated with CABG compared with DES (OR 0.46, 95% CI 0.29-0.71). There was a higher risk for stroke events in patients treated with CABG compared with DES (OR 2.02, 95% CI 1.20-3.41).
Composite outcomes of death, myocardial infarction, stroke and cerebrovascular events at the 5-year follow-up
At 5-year follow-up, MACEs showed a 40% significant reduction in patients who underwent CABG (OR 0.51, 95% CI 0.44-0.59). There was no significant difference between the two revascularization strategies in mortality (OR 0.92, 95% CI 0.77-1.11). There was a significantly lower risk for repeat revascularization by 70% in patients treated with CABG compared with DES (OR 0.27, 95% CI 0.20-0.34) and low risk for MI (OR 0.53, 95% CI 0.39-0.73). There was a higher risk for stroke events in patients treated with CABG compared with DES (OR 1.72, 95% CI 1.10-2.66).
Sensitive analysis
In our study, both fixed-and random-effect models were employed for sensitivity analysis. In observational studies, the χ 2 test for the Q statistic was 9.03 (P = 0.33) for MACEs, 3.70 (P = 0.88) for death, 2.69 (P = 0.84) for MI, 4.78 (P = 0.78) for stroke and 0.38 (P = 0.53) for repeat revascularization, indicating no significant heterogeneity among the studies. Therefore, the overall analysis from the fixed-effects model was robust. However, in random clinical trials, significant heterogeneity existed in MACEs, MI and repeat revascularization; the metaregression analysis showed that follow-up time has little effect on the MACEs and repeat revascularization. Estimate of between-study variance τ 2 for MI decreased from 0.30 to 0.14, but did not reach statistical significance 
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X. Li et al. / Interactive CardioVascular and Thoracic Surgery(P = 0.28). When the SYNTAX study was excluded, despite the I 2 value decreasing, pooled estimates of MACEs were similar and did not change materially; when the VA CARDS study was excluded, in spite of the decreasing I 2 value, the pooled estimates of repeat revascularization also changed materially (OR 0.24, 95% CI 0.19-0.31). No statistically significant heterogeneity was found in mortality and stroke event, indicating that the overall analysis from the fixed-effects model was robust.
Publication bias analysis
A funnel plot was used to assess the publication bias. Figure 7 shows the funnel plot for MACEs, death, MI, stroke and repeat revascularization. Although small studies with large standard errors tended to scatter above the horizontal line for MACEs, no publication bias was indicated (Egger's test: P = 0.406, Begg's test: P = 0.669). Similar pooled estimates for death (Egger's test: P = 0.245, Begg's test: P = 0.100), MI (Egger's test: P = 0.564, Begg's test: P = 0.815), stroke (Egger's test: P = 0.203, Begg's test: P = 0.312), repeat revascularization (Egger's test: P = 0.018, Begg's test: P = 0.244) were calculated.
DISCUSSION
That diabetes increase cardiovascular risk has been confirmed in a large population-based study. The long-term incidence of death or MI or long-term worse outcomes was higher in diabetic patients than in non-diabetics [18] [19] [20] [21] [22] [23] . The PCI approach was strongly recommended by the 2002 ACC/AHA Task Force on the management of patients with diabetes and multivessel CAD [24] . However, the recommendation was based on previous evidence before DESs were available [25] [26] [27] [28] [29] [30] [31] [32] . Many studies have shown that the DES is superior to the bare-metal stent in coronary artery revascularization, but the use of DESs in patients with diabetes and multivessel CAD remains controversial.
With 6653 patients with diabetes (3237 who underwent CABG and 3416 who underwent DES implantation) from 13 studies, our meta-analysis identified that CABG had a lower risk of MACEs compared with DES (15.7 vs 27.0%). Although there was no difference in death and MI in patients who underwent CABG and DES implantation (8.9 vs 10.2%, 4.5 vs 6.7%, respectively), the rate of occurrence of stroke events was 3.6% in CABG, much higher than in DES implantation (1.8%). The rate of incidence of repeat revascularization was higher in DES implantation compared with that in CABG (17.2 vs 5.6%). These results were consistent with previous studies [33] . At the 1-year follow-up, the rate of MACEs after CABG compared with DES implantation was relatively low (10.0 vs 17.5%). There was no difference in mortality, MI, stroke and repeat revascularization in patients who underwent CABG and DES implantation (3.2 vs 5.0%, 4.1 vs 3.1, 2.1 vs 0.3%, 3.6 vs 9.9%, respectively). The rate of MACEs after CABG compared with DES implantation was relative low at the 2-and 5-year follow-up (15.0 vs 17.5%, 18.5 vs 30.9%, respectively).
Our study has several limitations. First, publication bias might have occurred because our study was fully based on studies published in English-language journals. Studies in other languages and unpublished were not included. Although the pooled estimates did not change after we excluded studies with large ORs, we cannot completely rule out the possibility that the advantages of CABG were overestimated because of publication bias and patient selection criteria. Some may also argue that the true effect of two procedures on high-risk patients can be quantified from meta-analysis of studies with heterogeneous samples. We dealt with this concern primarily by using multiple sensitivity analysis; all of the analyses produced consistent pooled estimates, although false-positive findings are possible in the analysis because of small subgroups.
CONCLUSIONS
Our meta-analysis found that CABG continues to result in a significantly lower rate of MACEs compared with DES, primarily driven by less need for repeat revascularization. There was no difference in death and MI in patients who underwent CABG and DES implantation; however, the risk of stroke events was higher with CABG.
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